<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drugClass/">Drug classes</a></li>
      </ul>

      <h1>BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)</h1>

      <nav>
        <ul class="nav nav-list">

          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#drugsInClass" data-toggle="tab">Drugs in class</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Beta-blockers may cause intra-uterine growth restriction, neonatal hypoglycaemia, and bradycardia; the risk is greater in severe hypertension.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Asthma</li>
            <li>cardiogenic shock</li>
            <li>hypotension</li>
            <li>marked bradycardia</li>
            <li>metabolic acidosis</li>
            <li>phaeochromocytoma (apart from specific use with alpha-blockers)</li>
            <li>Prinzmetal&#8217;s angina</li>
            <li>second-degree AV block</li>
            <li>severe peripheral arterial disease</li>
            <li>sick sinus syndrome</li>
            <li>third-degree AV block</li>
            <li>uncontrolled heart failure</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Dry eyes (reversible on withdrawal), rashes (reversible on withdrawal),
              </p>
              <p>
                <strong>notKnown:</strong> Alopecia, bradycardia, bronchospasm, coldness of the extremities, conduction disorders, dizziness, dyspnoea, exacerbation of intermittent claudication, exacerbation of psoriasis, exacerbation of Raynaud&#8217;s phenomenon, fatigue, gastro-intestinal disturbances, headache, heart failure, hyperglycaemia (in patients with or without diabetes), hypoglycaemia (in patients with or without diabetes), hypotension, paraesthesia, peripheral vasoconstriction, psychoses, purpura, sexual dysfunction, sleep disturbances (with nightmares), symptoms of hypoglycaemia masked, thrombocytopenia, vertigo, visual disturbances,
              </p>
        
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">Bradycardia</p>
              <p>With administration by <b>intravenous injection</b>, excessive bradycardia can occur and may be countered with <b>intravenous injection</b> of atropine sulfate.</p>
            </section>
        
            <section class="overdosageInformation">
              <p>Therapeutic overdosages with beta-blockers may cause lightheadedness, dizziness, and possibly syncope as a result of bradycardia and hypotension; heart failure may be precipitated or exacerbated. For details on the management of poisoning, see Beta-blockers, under <xref format="dita" href="#PHP78558" type="bookmark" namespace="/treatment-summaries/emergency-treatment-of-poisoning">Emergency treatment of poisoning</xref>.</p>
            </section>
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Diabetes
          </li>
          <li>
            first-degree AV block
          </li>
          <li>
            history of obstructive airways disease (introduce cautiously)
          </li>
          <li>
            myasthenia gravis
          </li>
          <li>
            portal hypertension (risk of deterioration in liver function)
          </li>
          <li>
            psoriasis
          </li>
          <li>
            symptoms of hypoglycaemia may be masked
          </li>
          <li>
            symptoms of thyrotoxicosis may be masked
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
      </section>



      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Avoid abrupt withdrawal especially in ischaemic heart disease. Sudden cessation of a beta-blocker can cause a rebound worsening of myocardial ischaemia and therefore gradual reduction of dose is preferable when beta-blockers are to be stopped.</p>
            </section>
      </section>







      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

        
            <section class="crossSensitivity">
              <p>Caution is advised in patients with a history of hypersensitivity&#8212;may increase sensitivity to allergens and result in more serious hypersensitivity response. Furthermore beta-adrenoceptor blockers may reduce response to adrenaline (epinephrine).</p>
            </section>
      </section>

      <section class="tab-pane" id="drugsInClass">
        <h2>Drugs in the class of BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)</h2>

          <ul>
            <li><a href="../drug/PHP1001.html">NADOLOL</a></li>
            <li><a href="../drug/PHP1003.html">NEBIVOLOL</a></li>
            <li><a href="../drug/PHP1006.html">OXPRENOLOL HYDROCHLORIDE</a></li>
            <li><a href="../drug/PHP1013.html">PINDOLOL</a></li>
            <li><a href="../drug/PHP1020.html">SOTALOL HYDROCHLORIDE</a></li>
            <li><a href="../drug/PHP1025.html">TIMOLOL MALEATE</a></li>
            <li><a href="../drug/PHP944.html">PROPRANOLOL HYDROCHLORIDE</a></li>
            <li><a href="../drug/PHP952.html">ACEBUTOLOL</a></li>
            <li><a href="../drug/PHP954.html">ATENOLOL</a></li>
            <li><a href="../drug/PHP971.html">BISOPROLOL FUMARATE</a></li>
            <li><a href="../drug/PHP975.html">CARVEDILOL</a></li>
            <li><a href="../drug/PHP978.html">CELIPROLOL HYDROCHLORIDE</a></li>
            <li><a href="../drug/PHP983.html">CO-TENIDONE</a></li>
            <li><a href="../drug/PHP987.html">ESMOLOL HYDROCHLORIDE</a></li>
            <li><a href="../drug/PHP989.html">LABETALOL HYDROCHLORIDE</a></li>
            <li><a href="../drug/PHP993.html">METOPROLOL TARTRATE</a></li>
          </ul>
      </section>

    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
</body>
</html>
